Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0BFJ5)

Drug Name
RPSGL-Ig Drug Info
Indication
Disease Entry ICD 11 Status REF
Delayed graft function 4B24.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM0BFJ5

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P-selectin (SELP) TTE5VG0 LYAM3_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
P-selectin (SELP) DTT SELP 7.304 7.427 7.315 7.849
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Delayed graft function
ICD Disease Classification 4B24.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-selectin (SELP) DTT SELP 1.72E-04 1.23 0.86
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
2 rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.